Royal Bank of Canada
IMRX icon

Royal Bank of Canada’s Immuneering IMRX Stock Holding History

Royal Bank of Canada’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Buy
+360
New +$1.85K ﹤0.01% 6878
2025
Q4 		– Sell
-71,000
Closed -$497K – 7370
2025
Q3 		$497K Buy
71,000
+50,040
+239% +$260K ﹤0.01% 4477
2025
Q2 		$71K Buy
20,960
+20,959
+2,095,900% +$35.9K ﹤0.01% 5766
2025
Q1 		$0 Buy
+1
New +$2 ﹤0.01% 7016
2024
Q4 		– Sell
-11,294
Closed -$28K – 7059
2024
Q3 		$28K Buy
+11,294
New +$16.4K ﹤0.01% 5975
2024
Q2 		– Sell
-784
Closed -$2K – 7273
2024
Q1 		$2K Sell
784
-6,280
-89% -$35.2K ﹤0.01% 6677
2023
Q4 		$52K Buy
7,064
+2,507
+55% +$16.7K ﹤0.01% 5971
2023
Q3 		$35K Buy
4,557
+3,090
+211% +$28.4K ﹤0.01% 5962
2023
Q2 		$15K Buy
1,467
+1,462
+29,240% +$14.1K ﹤0.01% 6329
2023
Q1 		$0 Sell
5
-76
-94% -$432 ﹤0.01% 7251
2022
Q4 		$0 Buy
+81
New +$717 ﹤0.01% 7447
2022
Q2 		– Sell
-1,167
Closed -$8K – 7524
2022
Q1 		$8K Sell
1,167
-795
-41% -$7.64K ﹤0.01% 7054
2021
Q4 		$32K Buy
1,962
+1,090
+125% +$26.5K ﹤0.01% 6595
2021
Q3 		$23K Buy
+872
New +$23.4K ﹤0.01% 6628

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada's IMRX Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in Immuneering (IMRX) in Q1 2026: 360 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #6878 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in IMRX as recently as Q3 2025.

Royal Bank of Canada first reported a position in IMRX in Q3 2021 and has held it in 14 quarters since. The position peaked at $497K in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Royal Bank of Canada held 360 shares of Immuneering worth $1K as of Q1 2026.
  • Immuneering was a new Royal Bank of Canada position in Q1 2026.
  • Immuneering made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6878 holding.
  • Royal Bank of Canada first reported a position in Immuneering in Q3 2021 and has held it in 14 quarters since.
  • Royal Bank of Canada's Immuneering position peaked at $497K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.